Gallium Nitrate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Gallium Nitrate: From Radiopharmaceutical/Diagnostic Use to Plasma Cell Myeloma
One-Sentence Summary
Gallium nitrate is a gallium-based compound originally developed as an antineoplastic agent and used for cancer-related hypercalcemia. The gallium products registered in Singapore are radiopharmaceutical forms. The TxGNN model predicts it may be effective for plasma cell myeloma (the highest-ranked indication with published literature), with 0 registered clinical trials and 8 publications currently supporting this direction, mostly older and small-scale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration data (approved indication text is empty for both licences) |
| Predicted New Indication | Top-ranked prediction: sickle cell-hemoglobin C disease syndrome (prediction only). Best-supported prediction: plasma cell myeloma |
| TxGNN Prediction Score | 98.18% (sickle cell-hemoglobin C disease syndrome); 98.12% (plasma cell myeloma) |
| Evidence Level | L5 (sickle cell-hemoglobin C disease syndrome); L3 (plasma cell myeloma) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold (sickle cell-hemoglobin C disease syndrome); Proceed with Guardrails is not yet warranted for plasma cell myeloma, so treat it as a research question |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available in the data compiled for this report. Based on the literature, gallium nitrate inhibits osteoclast-mediated bone resorption and has antiproliferative effects. These are partly attributed to inhibition of ribonucleotide reductase and disruption of iron-dependent processes. A 1993 study also reported inhibition of protein tyrosine phosphatase, including in a colon cancer cell line.
The top-ranked predictions (sickle cell disease variants). The five sickle cell variants share an identical score of 98.18%. This suggests a shared parent-node signal in the knowledge graph rather than disease-specific evidence. No trials or publications were found, and a link through iron metabolism is speculative. The hereditary persistence of fetal hemoglobin variant is a milder genotype, so the rationale is weaker still.
Plasma cell myeloma. This is the most plausible prediction. Myeloma is characterised by osteoclast-driven bone destruction, which matches gallium nitrate's known effect on bone turnover and its history in cancer-related hypercalcemia. A pilot randomised study (1993) examined low-dose gallium nitrate for preventing osteolysis in myeloma. Two cohort reports describe prolonged survival in advanced-stage patients receiving it alongside chemotherapy. These data are old and small, with no comparison against modern myeloma therapies (bisphosphonates, proteasome inhibitors, immunomodulators). Gallium nitrate is also no longer a commonly used agent.
Other predictions. Colonic neoplasm has only one preclinical paper, and indolent myeloma, drug-induced osteoporosis and relapsing-remitting multiple sclerosis have no direct evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for any of the predicted indications.
Literature Evidence
Evidence for plasma cell myeloma:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8246033 | 1993 | Pilot RCT | Journal of Clinical Oncology | Low-dose gallium nitrate added to standard antimyeloma treatment, tested for preserving or increasing bone mass in osteolytic disease |
| 12776256 | 2003 | Cohort | Seminars in Oncology | Prolonged survival in advanced-stage myeloma patients given chemotherapy plus gallium nitrate |
| 12002765 | 2002 | Cohort | Leukemia & Lymphoma | 13 of 167 patients on the M-2 protocol received adjuvant gallium nitrate for osteolysis, with extended survival reported |
| 12776253 | 2003 | Review | Seminars in Oncology | Gallium nitrate is highly effective in cancer-related hypercalcemia, with non-cytotoxic effects on bone |
| 12776254 | 2003 | Review | Seminars in Oncology | Effects on bone resorption distinct from bisphosphonates; possible broader use in myeloma, bone metastases, Paget's disease and osteoporosis |
| 9362436 | 1997 | Review | Cancer | Potent effects on bone turnover; randomised double-blind studies suggested efficacy relative to etidronate, calcitonin and pamidronate in hypercalcemia |
| 3533251 | 1986 | Review | Cancer Treatment Reports | Antitumour activity in murine models; renal dose-limiting toxicity in animals |
| 24021907 | 2014 | Review | American Journal of Kidney Diseases | Approach to hypercalcemia of malignancy, including myeloma-related osteolysis |
Evidence for colonic neoplasm:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8467506 | 1993 | Preclinical/Mechanistic | Cancer Research | Gallium nitrate inhibited protein tyrosine phosphatase (IC50 2-6 µM) in Jurkat and HT-29 colon cancer cell membranes; no clinical data |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09913P | Gallium Citrate (Ga 67) Injection 37 MBq/ml | Injection | Not stated |
| SIN16844P | Galliapharm Radionuclide Generator 0.74–1.85 GBq | Injection, solution (radiopharmaceutical) | Not stated |
Both licences are valid single-ingredient products. Both are radiopharmaceutical gallium preparations, not gallium nitrate therapeutic formulations, so they do not directly support the predicted therapeutic uses.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Originally developed as an antineoplastic agent; also acts non-cytotoxically on bone. Please refer to the package insert warnings and precautions |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Renal function (renal toxicity was dose-limiting in animal studies), plus haematological parameters and electrolytes |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 33 interactions were identified; the main ones listed below are mostly flagged for additive nephrotoxicity.
- Major: amphotericin B (including lipid complex, cholesteryl sulfate and liposomal forms), the aminoglycosides kanamycin, neomycin and streptomycin, deferasirox, and iodinated contrast agents (iothalamic acid, diatrizoate, iopromide, iopamidol, iohexol, iodipamide, iodixanol)
- Moderate: balsalazide, mesalazine, olsalazine, sulfasalazine, exenatide
- Animal studies identified renal toxicity as dose-limiting (PMID 3533251).
Package insert warnings and contraindications are not available in the data compiled for this report; please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold (overall). Plasma cell myeloma is the only prediction worth pursuing, as a research question.
Rationale:
- The highest-scoring predictions (sickle cell variants) are model output only, with no trials or literature, and share an identical score that suggests a parent-node artefact.
- For plasma cell myeloma there is a plausible mechanism and limited evidence (L3), but it is old, small-scale and uncompared with current standards of care. The Singapore-registered gallium products are radiopharmaceuticals, not therapeutic gallium nitrate.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data
- Confirmation of the study design of the myeloma survival reports and a comparison with current myeloma regimens
- Confirmation of whether a therapeutic gallium nitrate formulation is available in Singapore, and the route compatibility
- A renal safety plan, given the major interactions with nephrotoxic agents
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.